An observational study in Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis and Sarcoidosis, sponsored by University of Virginia. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by University of Virginia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Lung Diseases, Interstitial with a site in United States — 67 open to participants now, 83 under way, 19 of them phase 3. Lung Diseases, Interstitial · United States.
Among the 201 studies in Lung Diseases, Interstitial with a site in United States, this one is the 11th largest by planned enrollment of the 60 observational ones that give a count, is one of 9 that started in 2018, is one of 61 observational ones, reaches primary completion later than 82 of the 82 other live ones, and was the 112th registered.
681 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →67 of the 201 studies in Lung Diseases, Interstitial with a site in United States are open now. Recruiting first, the newest first:
Insmed Incorporated · Sites in United States
Ages 18–85
Tectonic Operating Company, Inc. · Sites in United States, Poland, Romania and 3 more countries
Ages 18–80
University of California, San Francisco · Sites in United States
Ages 18+
NS Pharma, Inc. · Sites in United States, Japan
Ages 18–80
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 61 · Phase 3 37 · Phase 4 5
First in 1999; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 157 across 278 observational studies indexed under Lung Diseases, Interstitial.
Median enrollment 53 across the 138 interventional studies, 327 across the 60 observational. Of the 105 that completed or were terminated, 51 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 201 have an industry lead sponsor. The 10 most frequent:
University of Virginia is the lead sponsor of 677 studies on the registry; 139 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.
University of Virginia has 3 studies filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
25 of the studies in Lung Diseases, Interstitial with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06806592Phase 3Boehringer IngelheimA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | 2027-04-15 |
| NCT05943535Phase 3United TherapeuticsStudy of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | 2027-11 |
| NCT06195072Scleroderma Research Foundation, Inc.Platform Clinical Study for Conquering Scleroderma | 2026-11 |
| NCT07333183Pulmovant, Inc.A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD | 2026-12 |
Add all 25 to your calendar (.ics) → With an account.
Among the 201 studies in Lung Diseases, Interstitial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Data and specimens will be collected longitudinally from patients seen in the UVA Interstitial Lung Disease (ILD) clinic in order to describe the phenotypic expression of various interstitial lung diseases. Samples will also be collected from a control group for comparison purposes.
All data will be entered into a repository for future research purposes or screening for new studies that become available. This data will help identify trends and hopefully lead to a better understanding of the disease progression, treatment options, and outcomes.
Following the clinical course of patients with ILD will allow description of the natural history of these diseases and prospective analysis of the following specific questions:
Patients receiving care in the UVA ILD or Pulmonary clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with Interstitial Lung Disease seen at the UVA ILD or Pulmonary Clinic
Other: Interstitial Lung Disease
Control group of patients and family members of those with an Interstitial Lung Disease
Not applicable - this is not an interventional trial
Clinical Course of Disease
Course of disease in patients with ILD will be reviewed prospectively for the duration of the study
Time frame: Yearly from date of consent until subject is lost to follow-up or death occurs, whichever comes first, assessed up to 144 months
Subject deaths
Causes of death in patients with ILD will be reviewed prospectively for the duration of the study
Time frame: Yearly from date of consent until subject is lost to follow-up or death occurs, whichever comes first, assessed up to 144 months
Plan to share: Undecided — Coded and de-identified data and specimens will be shared with collaborators. MTAs and DUAs are in place for such collaborations. This study also includes a data security plan that includes protective measures for sharing of data between investigators.
No publications or documents are linked to this record.
Started Aug 2018 (actual). Primary completion is estimated for Aug 2035, 204 months after the start.
Of 111 non-industry observational studies under Lung Diseases, Interstitial, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 274. This study's planned 204 months is above that.
Counting every sponsor, half of 132 studies reached it within 55 months; a quarter within 31 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.